Health benefits company WellPoint has announced that it will cover Rotarix, a rotavirus vaccine designed to prevent a virus which causes vomiting and diarrhea in infants and children.
This decision to cover Rotarix, manufactured by GlaxoSmithKline, is based on formal recommendations announced by the US Centers for Disease Control and Prevention’s advisory committee on Immunization Practices (ACIP).
ACIP recommended that Rotarix be added to the list of recommended inoculations offered to infants. Rotarix is a liquid given in a two-dose series to infants 6-24 weeks old.
WellPoint said that its immunization policy decisions are based on recommendations issued by ACIP and other nationally recognized organizations. The vaccine will be covered for infants whose benefit plans provide coverage for vaccines.